Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVSEF) Revenue (2016 - 2025)

Historic Revenue for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to $828.0 million.

  • Novartis Ag's Revenue fell 9370.49% to $828.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.3 billion, marking a year-over-year decrease of 9346.94%. This contributed to the annual value of $54.5 billion for FY2025, which is 837.69% up from last year.
  • As of Q4 2025, Novartis Ag's Revenue stood at $828.0 million, which was down 9370.49% from $730.0 million recorded in Q3 2025.
  • Over the past 5 years, Novartis Ag's Revenue peaked at $13.2 billion during Q4 2021, and registered a low of $657.0 million during Q1 2025.
  • Its 5-year average for Revenue is $9.9 billion, with a median of $11.8 billion in 2023.
  • Per our database at Business Quant, Novartis Ag's Revenue soared by 1514.49% in 2024 and then crashed by 9444.59% in 2025.
  • Novartis Ag's Revenue (Quarter) stood at $13.2 billion in 2021, then decreased by 20.05% to $10.6 billion in 2022, then grew by 8.01% to $11.4 billion in 2023, then grew by 15.14% to $13.2 billion in 2024, then tumbled by 93.7% to $828.0 million in 2025.
  • Its Revenue stands at $828.0 million for Q4 2025, versus $730.0 million for Q3 2025 and $1.1 billion for Q2 2025.